Brigatinib

(Alunbrig®)

Alunbrig®

Drug updated on 12/11/2024

Dosage FormTablet (oral; 30 mg, 90 mg, 180 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 23 systematic review(s)/meta-analysis(es). [1-23]
  • Brigatinib significantly improved Progression-Free Survival (PFS) compared to crizotinib (hazard ratio (HR): 0.48, 95% confidence interval (CI): 0.35 to 0.66) and showed varying PFS across treatment lines, including 24.00 months in first-line, 16.26 months post-crizotinib, and 12.96 months after any prior Anaplastic Lymphoma Kinase (ALK)-Tyrosine Kinase Inhibitor (TKI).
  • Brigatinib had a pooled Objective Response Rate (ORR) of 64% (95% CI: 45%-83%), with no significant differences in ORR when compared to alectinib and lorlatinib.
  • Brigatinib demonstrated robust intracranial efficacy, with an intracranial PFS of 19.26 months in patients with brain metastases and the lowest Number Needed to Treat (NNT) for intracranial outcomes alongside lorlatinib.
  • No significant differences in Overall Survival (OS) were observed between brigatinib and other next-generation ALK inhibitors.
  • Brigatinib had higher rates of grade 3-4 adverse events (63.7%) compared to alectinib (16.2%) but lower compared to lorlatinib (91.6%). Common adverse events included increased Creatine Phosphokinase (CPK) (44%), diarrhea (37%), and nausea (28%).
  • Brigatinib was associated with a lower risk of total thromboembolism (odds ratio (OR): 0.31; 95% credible interval (CrI): 0.11 to 0.79) and venous thromboembolism (OR: 0.18; 95% CrI: 0.04 to 0.6) compared to crizotinib.
  • Brigatinib had the highest incidence of all-grade pneumonitis (7.09%) and high-grade pneumonitis (3.06%) among ALK TKIs.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Alunbrig (brigatinib) Prescribing Information.2022Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)2024Lung Cancer (Amsterdam, Netherlands)
Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis2024BMJ Open
Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naive advanced ALK-positive non-small cell lung cancer: a systematic review and network meta-analysis2024Translational Lung Cancer Research
The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis2024Cancer Treatment and Research Communications
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis2024BMC Cancer
Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis2023Lung Cancer (Amsterdam, Netherlands)
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer2023Cancer Medicine
Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis2023Lung Cancer Management
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden2023Applied Health Economics and Health Policy
Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis2023Cancer Medicine
Comparative Efficacy of ALK Inhibitors for Treatment-Naive ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis2023International Journal of Molecular Sciences
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis2023Cancer
Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis2022Frontiers in Oncology
Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison2022Journal of Clinical Medicine
Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis2022Frontiers in Pharmacology
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer2022The Cochrane Database of Systematic Reviews
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials2021BMC Cancer
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis2021Journal of Clinical Medicine
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis2021Lung Cancer (Amsterdam, Netherlands)
Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis2021Cancers
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naive ALK-Positive Lung Cancer2021Cancers
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis2020Cancers
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis2020PloS One

Clinical Practice Guidelines